계명대학교 의학도서관 Repository

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients

Metadata Downloads
Author(s)
Nack Cheon BaeMyung Hwa ChaeMyung Hoon LeeKyung Mee KimEung Bae LeeChang Ho KimTae-In ParkSung Beom HanSanghoon JheonTae Hoon JungJae Yong Park
Keimyung Author(s)
Han, Sung Beom
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Genetics and Cytogenetics
Issued Date
2007
Volume
173
Issue
2
Abstract
The epidermal growth factor receptor (EGFR), and its family members play an important role in the development and progression of lung cancers. It has been reported that somatic mutations in the tyrosine kinase domain of the EGFR or ERBB2 genes occur in a subset of patients with lung cancer. We searched for mutations of the EGFR, ERBB2, and KRAS genes in surgically resected non-small cell lung cancers (NSCLCs) to determine the prevalence of these mutations in Korean lung cancer patients. In addition, we examined the relationship between the mutations and clinicopathologic features of lung cancers. Mutations of the EGFR, ERBB2, and KRAS genes were determined by polymerase chain reaction–based direct sequencing in 115 surgically resected non-small cell lung cancers. EGFR mutations were present in 20 patients (17.4%). The EGFR mutations were found only in adenocarcinomas (20 of 55 adenocarcinomas, 36.4%). The ERBB2 mutation was found in 1 adenocarcinoma of the 115 NSCLCs (0.9% overall; 1.8% of the 55 adenocarcinomas). KRAS mutations were found in 6 (5.2%) of the 115 NSCLCs (2 of 60 squamous cell carcinomas, or 3.3%, and 4 of 55 adenocarcinomas, or 7.3%). EGFR mutations in adenocarcinomas were more frequent in women (P = 0.02) and in never-smokers (P = 0.004). EGFR mutations in adenocarcinomas were not associated with pathologic stage in never-smokers, but were more frequent in pathologic stage II–IV than in stage I in ever-smokers (P = 0.01). Of the 55 adenocarcinomas, 25 (45.5%) had mutations of one or another of the three genes; EGFR mutations were never found in adenocarcinomas together with ERBB2 or KRAS mutations. These findings suggest that the EGFR mutation is frequent in Korean lung cancer patients, and that the ERBB2 mutation is rare. Further studies are needed to investigate the role of EGFR mutations in the carcinogenesis of adenocarcinoma among smokers.
Keimyung Author(s)(Kor)
한승범
Publisher
School of Medicine
Citation
Nack Cheon Bae et al. (2007). EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genetics and Cytogenetics, 173(2), 107–113. doi: 10.1016/j.cancergencyto.2006.10.007
Type
Article
ISSN
0165-4608
Source
https://www.sciencedirect.com/science/article/pii/S0165460806007060?via%3Dihub
DOI
10.1016/j.cancergencyto.2006.10.007
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35307
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.